What one share of Agenus holds
Agenus is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious disease. Our primary business is immuno-oncology ("I-O"), where we are advancing antibody-based programs to activate innate and adaptive immunity, overcome tumor immune evasion and expand the population of patients who may benefit from immunotherapy.
Agenus’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $3.63 |
|---|---|
| Profit | $2.51 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$2.69 |
| Cash and investments | $0.44 |
| Debt | $0.71 |
| Book value | −$4.67 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2022 | $6.96 | −$15.64 | $3.77 | −$16.22 | — | — |
| 2023 | $8.74 | −$13.75 | $0.56 | −$13.09 | — | −$8.13 |
| 2024 | $4.82 | −$10.59 | $0.03 | −$7.40 | — | −$13.81 |
| 2025 | $3.84 | −$0.00 | $0.00 | −$2.60 | — | −$7.68 |
Common questions about Agenus
How much does one share of Agenus earn?
Over the last 12 months, each share of Agenus earned $2.51 of profit on $3.63 of sales, keeping about 69¢ of every $1 (profit margin).
Does Agenus pay a dividend?
Agenus didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Agenus’s book value per share?
Agenus’s book value is negative (−$4.67 per share): it owes more than everything it owns is recorded at, often after years of buying back its own shares, as of June 30, 2026.
How much cash and debt does each share of Agenus have?
Each share of Agenus has $0.44 of cash and investments and $0.71 of debt, as of June 30, 2026.
What is Agenus’s free cash flow per share?
−$2.69 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has Agenus bought back shares?
Agenus’s share count rose about 111% from 2022 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.